Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2026)

Recursion Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $32.8 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 17.29% year-over-year to $32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (down 17.29% YoY) and the FY2025 annual result came in at $37.6 million, down 39.12% from the prior year.
• Current Deferred Revenue was $32.8 million for Q1 2026 at Recursion Pharmaceuticals, down from $37.6 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $73.1 million in Q2 2023 and bottomed at $32.2 million in Q2 2024.
• A 5-year average of $49.4 million and a median of $47.4 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 537.81% — and 2024, when it plunged 55.95%.
• Recursion Pharmaceuticals' Current Deferred Revenue stood at $56.7 million in 2022, then tumbled by 35.79% to $36.4 million in 2023, then surged by 69.57% to $61.8 million in 2024, then slumped by 39.12% to $37.6 million in 2025, then fell by 12.79% to $32.8 million in 2026.
• Business Quant data shows RXRX's Current Deferred Revenue at $32.8 million in Q1 2026, $37.6 million in Q4 2025, and $47.4 million in Q3 2025.